Related Experiment Video
Updated: Oct 5, 2025

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry
Published on: July 13, 2019
Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials
Hannah Imlay1, Paul Baum2, Daniel C Brennan3
1Department of Internal Medicine, University of Utah, Salt Lake City, Utah, USA.
Background:
BK polyomavirus (BKPyV) infection and BK polyomavirus nephropathy (BKPyVAN) are important causes of allograft dysfunction and premature allograft loss in renal transplant recipients.
Results And Discussion:
Controlled clinical trials to evaluate new agents for prevention and treatment are needed but are hampered by the lack of outcome measures that accurately assess the effect of the intervention, are clinically relevant, and are acceptable from a regulatory perspective.
Methods:
To facilitate consistent end points in clinical trials and to support clinical research and drug development, definitions of BKPyV infection and disease have been developed by the BK Disease Definitions Working Group of the Transplantation Associated Virus Infection Forum with the Forum for Collaborative Research, which consists of scientists, clinicians, regulators, and industry representatives.
Conclusions:
These definitions refine established principles of "proven" BKPyV disease and introduce a "probable" disease category that could be used in clinical trials to prevent or treat BKPyVAN in renal transplant recipients.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury III: Clinical Manifestations
Acute Pyelonephritis II: Diagnostic Studies and Management

